Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 10/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662090 | 1.00 | OPRD1 (0.45) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL9348476 | 0.87 | ALDH1A1 (0.47) | OPRD1OPRK1RORC | |
| SCHEMBL29662079 | 0.87 | ALDH1A1 (0.47) | OPRD1OPRK1RORC | |
| SCHEMBL9345760 | 0.86 | OPRD1 (0.46) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL29662112 | 0.83 | PDK1 (0.48) | JAK2JAK1STSRORCTACR1 | |
| SCHEMBL22950454 | 0.82 | RORC (0.42) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL20520705 | 0.81 | OPRD1 (0.42) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL9041256 | 0.76 | MC4R (0.41) | — | |
| SCHEMBL8042358 | 0.76 | PDK1 (0.44) | OPRD1OPRK1JAK2JAK1GPR119 | |
| SCHEMBL1489139 | 0.76 | OPRD1 (0.44) | OPRD1OPRK1JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021018237-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-02-04 | — | — | WO | disclosed |